Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Rhea-AI Summary

Pelthos Therapeutics (NYSE American: PTHS) will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. A conference call and Q&A will be held at 8:00 a.m. Eastern Time the same day.

Investors can join via toll-free dial-in, international number, conference ID 13758894, or a live webcast at the provided URL.

News Market Reaction – PTHS

-0.30%

1 alert

-0.30% News Effect

On the day this news was published, PTHS declined 0.30%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings date: March 19, 2026 Conference time: 8:00 a.m. Eastern Time Toll-free number: 1-877-451-6152 +2 more

5 metrics

Earnings date March 19, 2026 Scheduled Q4 and full-year 2025 results release

Conference time 8:00 a.m. Eastern Time Start of earnings conference call

Toll-free number 1-877-451-6152 U.S. dial-in for earnings call

International number 1-201-389-0879 International dial-in for earnings call

Conference ID 13758894 Access code for earnings conference call

Market Reality Check

Price: $22.00 Vol: Volume 2,622 is below the...

low vol

$22.00 Last Close

Volume Volume 2,622 is below the 20-day average of 6,413 (relative volume 0.41). low

Technical Price at 23.12 trades below the 200-day MA of 26 and between the 52-week low 13.76 and high 54.29.

Peers on Argus

PTHS was up 3.17% with mixed peers: IFRX, MEIP, and PLRX up between 4.72–6.59%, ...

3 Up

PTHS was up 3.17% with mixed peers: IFRX, MEIP, and PLRX up between 4.72–6.59%, while HYFT and ORMP were down 4.31% and 2.52%. Momentum scanner showed STTK, IFRX, and ANIX moving up without same-day news, and overall sector move was flagged as false, suggesting stock-specific factors.

Historical Context

5 past events · Latest: Feb 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 23	Conference appearance	Positive	+5.0%	CEO presentation at Oppenheimer healthcare conference with webcast and meetings.
Jan 13	Debt financing	Positive	-1.3%	Up to $50M senior secured term loan facility to support product launches.
Jan 05	Product acquisition	Positive	-9.0%	Acquisition of FDA-approved Xeglyze head-lice treatment for $1.8M.
Dec 23	Board appointment	Neutral	-1.8%	Appointment of experienced finance executive Andrew Einhorn to board roles.
Dec 04	Access agreement	Positive	+0.6%	PBM agreement expanding ZELSUVMI access to over 20M covered lives.

Pattern Detected

Recent positive commercial and financing news has produced mixed share reactions, with some strategic wins sold off and some events bid up.

Recent Company History

Over the last few months, Pelthos has focused on commercialization and balance sheet actions. A PBM deal expanding ZELSUVMI access on Dec 4, 2025 saw only a modest 0.61% move. The Xeglyze acquisition on Jan 5, 2026 coincided with a -9.03% reaction. The Horizon term loan on Jan 13, 2026 led to a slight -1.31% move, while an Oppenheimer conference appearance on Feb 23, 2026 aligned with a 5.04% gain. Today’s earnings-date notice fits into this ongoing commercial build-out and financing story.

Regulatory & Risk Context

Active S-3 Shelf · $200,000,000

Shelf Active

Active S-3 Shelf Registration 2026-02-02

$200,000,000 registered capacity

An effective S-3 shelf filed on 2026-02-02 allows Pelthos to offer up to $200,000,000 in various securities over time. The company has already used this shelf for a 424B3 resale registration on 2026-02-13. The filing highlights a going concern qualification, an accumulated deficit of about $43.1 million as of September 30, 2025, and ongoing net losses, underscoring financing and dilution risk.

Market Pulse Summary

This announcement sets March 19, 2026 for Pelthos’s Q4 and full-year 2025 results, with a conference...

Analysis

This announcement sets March 19, 2026 for Pelthos’s Q4 and full-year 2025 results, with a conference call at 8:00 a.m. Eastern Time. Investors will be able to assess progress on commercializing ZELSUVMI and integrating recent financing and acquisition moves. Regulatory filings highlight a going concern qualification, an accumulated deficit near $43.1 million, and an active $200,000,000 shelf, making cash runway, revenue trends, and any capital-raising updates key items to watch in the upcoming report.

AI-generated analysis. Not financial advice.

Company to hold a conference call at 8:00 a.m. ET

DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. The company will hold a conference call followed by a question-and-answer period at 8:00 a.m. Eastern Time.

Details for the conference call can be found below:

Date:	Thursday, March 19, 2026
Time:	8:00 a.m. Eastern Time
Toll Free:	1-877-451-6152
International:	1-201-389-0879
Conf.ID:	13758894
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753536&tp_key=4e91699655

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat Molluscum contagiosum. The company’s portfolio of assets includes Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

FAQ

When will Pelthos Therapeutics (PTHS) report Q4 and full year 2025 results?

Pelthos Therapeutics will report results on March 19, 2026 with a conference call at 8:00 a.m. ET. According to Pelthos Therapeutics, the company will release fourth quarter and full year 2025 financial results and host a follow-up Q&A for investors.

How can investors join the Pelthos Therapeutics (PTHS) earnings call on March 19, 2026?

Investors may join by dialing the toll-free number or international line using conference ID 13758894. According to Pelthos Therapeutics, a live webcast link is also provided for online access during the 8:00 a.m. ET call.

Will Pelthos Therapeutics (PTHS) provide a webcast for the March 19, 2026 call?

Yes. A live webcast will be available via the company's provided URL for the March 19, 2026 8:00 a.m. ET call. According to Pelthos Therapeutics, the webcast link allows investors to listen to the financial results and Q&A online.

What time is the Pelthos Therapeutics (PTHS) conference call for the Q4 2025 results?

The conference call is scheduled for 8:00 a.m. Eastern Time on March 19, 2026. According to Pelthos Therapeutics, the call will include presentation of results followed by a question-and-answer period for investors and analysts.

What information should shareholders expect from Pelthos Therapeutics' (PTHS) March 19, 2026 announcement?

Shareholders should expect fourth quarter and full year 2025 financial results and a management Q&A on the March 19, 2026 call at 8:00 a.m. ET. According to Pelthos Therapeutics, the company will present financial performance details and answer investor questions.